No Data
No Data
Biotech IPOs Return as Sector Recovers After Funding Overhang
Cassava Sciences Stock Sinks 14% After $40 Million Settlement With SEC
Healthcare Venture Investors Ante Up. Public Markets Remain Cool. -- Barrons.com
SPDR S&P Biotech ETF To Go Ex-Dividend On September 23rd, 2024 With 0.01523 USD Dividend Per Share
Halozyme Cut to Neutral at J.P. Morgan on Valuation
These four companies that are about to debut on the US stock market are worth focusing on. They may reverse the downturn in Biotech IPOs.
BioAge and Bicara hope to reverse the recent trend of obstacles in biotech companies' IPO in the US stock market; The binary nature of drug development has kept some investors away from the biotech industry.